Validity of the self-administered comorbidity questionnaire in patients with inflammatory bowel disease
-
Published:2023-01
Issue:
Volume:16
Page:
-
ISSN:1756-2848
-
Container-title:Therapeutic Advances in Gastroenterology
-
language:en
-
Short-container-title:Therap Adv Gastroenterol
Author:
van Linschoten Reinier Cornelis Anthonius12ORCID, Huberts Anouk Sjoukje3, van Leeuwen Nikki4, Hazelzet Jan Antonius4, van der Woude Janneke2, West Rachel Louise5, van Noord Desirée5, de Jonge V., Wolfhagen F. H. J., Bodelier A. G. L., Hoekstra J., van der Woude C. J., de Vries A. C., West R. L., van Noord D., van Linschoten R. C. A., Visser E., Verweij K. E., Kubben F. J. G. M., Holster I.L., Fitzpatrick C. E., Robbers K., Vermeulen H. G., van der Wiel S. K., Jansen S. V.
Affiliation:
1. Department of Gastroenterology & Hepatology, Franciscus Gasthuis & Vlietland, P.O Box 10900, Rotterdam 3004BA, Netherlands 2. Department of Gastroenterology & Hepatology, Erasmus MC, Rotterdam, Netherlands 3. Department of Quality and Patientcare, Erasmus MC, Rotterdam, Zuid-Holland, Netherlands 4. Department of Public Health, Erasmus University Medical Center, Rotterdam, Zuid-Holland, Netherlands 5. Department of Gastroenterology & Hepatology, Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands
Abstract
Background: The International Consortium for Health Outcomes Measurement has selected the self-administered comorbidity questionnaire (SCQ) to adjust case-mix when comparing outcomes of inflammatory bowel disease (IBD) treatment between healthcare providers. However, the SCQ has not been validated for use in IBD patients. Objectives: We assessed the validity of the SCQ for measuring comorbidities in IBD patients. Design: Cohort study. Methods: We assessed the criterion validity of the SCQ for IBD patients by comparing patient-reported and clinician-reported comorbidities (as noted in the electronic health record) of the 13 diseases of the SCQ using Cohen’s kappa. Construct validity was assessed using the Spearman correlation coefficient between the SCQ and the Charlson Comorbidity Index (CCI), clinician-reported SCQ, quality of life, IBD-related healthcare and productivity costs, prevalence of disability, and IBD disease activity. We assessed responsiveness by correlating changes in the SCQ with changes in healthcare costs, productivity costs, quality of life, and disease activity after 15 months. Results: We included 613 patients. At least fair agreement (κ > 0.20) was found for most comorbidities, but the agreement was slight (κ < 0.20) for stomach disease [κ = 0.19, 95% CI (−0.03; 0.41)], blood disease [κ = 0.02, 95% CI (−0.06; 0.11)], and back pain [κ = 0.18, 95% CI (0.11; 0.25)]. Correlations were found between the SCQ and the clinician-reported SCQ [ρ = 0.60, 95% CI (0.55; 0.66)], CCI [ρ = 0.39, 95% CI (0.31; 0.45)], the prevalence of disability [ρ = 0.23, 95% CI (0.15; 0.32)], and quality of life [ρ = −0.30, 95% CI (−0.37; −0.22)], but not between the SCQ and healthcare or productivity costs or disease activity (|ρ| ⩽ 0.2). A change in the SCQ after 15 months was not correlated with a change in any of the outcomes. Conclusion: The SCQ is a valid tool for measuring comorbidity in IBD patients, but face and content validity should be improved before being used to correct case-mix differences.
Publisher
SAGE Publications
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|